Skip to main content
Equasens logo

Equasens — Investor Relations & Filings

Ticker · EQS ISIN · FR0012882389 LEI · 96950066I7XVFGZI8L92 PA Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 326 across all filing types
Latest filing 2021-04-19 Regulatory Filings
Country FR France
Listing PA EQS

About Equasens

https://equasens.com

Equasens is a company specializing in healthcare IT solutions for professionals and establishments. It develops and provides a range of products including professional software, electronic equipment, connected devices, and digital health solutions. The company's offerings cater to a diverse client base, including pharmacies, hospitals, nursing homes (EHPADs), home care services, and independent medical practitioners. The primary objective of its solutions is to improve the quality of patient care by facilitating the secure sharing of health data, enhancing communication between different care providers, and optimizing the coordination of care pathways across outpatient, hospital, and home care settings.

Recent filings

Filing Released Lang Actions
Pharmagest Interactive: Strategic partnership with Elsan
Regulatory Filings Classification · 1% confidence The document is clearly labeled as a "PRESS RELEASE" and details a strategic partnership, an acquisition of a minority stake, and the deployment of a technology solution (PandaLab Pro) between ELSAN and Pharmagest Group. This type of announcement, detailing corporate strategy, partnerships, and minor equity movements, does not fit the definitions for standard periodic financial reports (10-K, IR, ER, MRQ) or specific regulatory filings (DIV, DIRS, DVA). It is a corporate announcement regarding business development and investment. Since it is not a standard regulatory filing like a 10-K or a specific event report (like AGM or Dividend), and it is not merely announcing the publication of another report (RPA), the most appropriate general category for a significant corporate development announcement that doesn't fit elsewhere is 'Regulatory Filings' (RNS) as a catch-all for material non-standard announcements, or potentially 'Capital/Financing Update' (CAP) due to the minority stake acquisition. However, the primary focus is the strategic partnership and business expansion, which often falls under general corporate news. Given the options, and recognizing this is a material business event announcement, RNS serves as the best fit if a more specific category like 'M&A Activity' (TAR) is not applicable (as this is a minority stake, not a full merger/takeover). Since it involves a strategic partnership and a minority investment, it is a significant corporate action announcement. I will classify it as RNS as it is a general press release announcing a material business event that doesn't fit the other specific categories.
2021-04-19 English
PHARMAGEST GROUP strengthens its network in Paris Regions by acquiring ADI
M&A Activity Classification · 1% confidence The document is titled 'PRESS RELEASE' and announces a specific corporate action: Pharmagest Group acquiring the remaining 50% stake in its historic distributor, ADI. This is a material event concerning corporate structure and strategy, but it is not a standard periodic financial report (like 10-K or IR), a dividend announcement, or a management change announcement. It is a specific corporate transaction announcement. Among the provided codes, 'TAR' (M&A Activity) is the closest fit for an acquisition, although this is a 100% acquisition of a subsidiary/distributor rather than a merger or takeover bid of a separate entity. However, given the nature of the transaction (acquiring a business entity), TAR is the most appropriate classification for a significant corporate transaction announcement that isn't explicitly covered by other codes like CAP or DIV. It is clearly not an ER, CT, or AGM-R. Since it is a press release announcing a specific corporate action, it is not an RPA or RNS fallback.
2021-03-01 English
Pharmagest renforce son réseau en Ile-de-France et rachète son distributeur ADI
M&A Activity Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces a specific corporate action: the acquisition of a 50% stake in ADI, making Groupe Pharmagest the sole shareholder. This type of announcement, detailing a merger, acquisition, or significant corporate transaction, directly corresponds to the M&A Activity category. Although it mentions future financial calendar dates, the primary focus and content are about the takeover/acquisition. This fits the definition for M&A Activity (Code: TAR) better than a general Regulatory Filing (RNS) or a Capital/Financing Update (CAP), as it is a specific transaction announcement.
2021-03-01 French
Franchissement de seuils
Major Shareholding Notification Classification · 1% confidence The document is titled "Déclaration de franchissement de seuils (article L. 233-7 du code de commerce)" which translates to 'Declaration of crossing thresholds (Article L. 233-7 of the Commercial Code)'. This explicitly indicates a notification regarding changes in significant share ownership, crossing ownership thresholds (in this case, falling below 5% and holding zero shares). This aligns perfectly with the definition for Major Shareholding Notification (MRQ). The document is short and contains the required declaration details.
2021-02-19 French
PHARMAGEST INTERACTIVE : Chiffre d’affaires 2020 à 171,75 M€ en progression de 8,32%
Earnings Release Classification · 1% confidence The document provides a detailed summary of the company's financial performance for the year 2020, including revenue figures broken down by quarter and division, comparisons to 2019, commentary on business segments, and future outlook ('Perspectives 2021'). It explicitly mentions 'Chiffre d'affaires 2020' (2020 Revenue) and includes a table summarizing annual revenue. Crucially, it announces the 'Résultats Annuels 2020' (Annual Results 2020) release date (March 26, 2021) and a subsequent meeting. This content structure—a comprehensive review of the full fiscal year's performance—is characteristic of an Earnings Release (ER) or the financial highlights section often preceding a full Annual Report (10-K). Since it focuses heavily on summarizing the *results* for the period rather than being the full statutory 10-K filing or a formal presentation (IP), and given the context of announcing the 'Annual Results', the most fitting classification is Earnings Release (ER). It is not a full 10-K as it lacks the comprehensive statutory disclosures typically found in that filing, nor is it a mere announcement of a report (RPA) as it contains substantial data. FY 2020
2021-02-04 French
Pharmagest Interactive: 2020 annual sales: €171.75 million, +8.32%
Earnings Release Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and provides preliminary, unaudited financial figures for the full year 2020, including revenue breakdowns by quarter and division, along with a 2021 outlook. This format, focusing on key financial highlights released before the official audited report, strongly indicates an Earnings Release (ER). It is not the comprehensive Annual Report (10-K) because it states the '2020 Annual Results' will be released later (March 26, 2021), and the figures are marked as '* unaudited*'. It is too detailed for a simple Report Publication Announcement (RPA) as it contains the actual results summary. FY 2020
2021-02-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.